key: cord-0260927-tjqbrypl
authors: Gibbins, Matthew P.; Müller, Katja; Glover, Maya; Liu, Jasmine; Putrianti, Elyzana D.; Bauza, Karolis; Reyes-Sandoval, Arturo; Matuschewski, Kai; Silvie, Olivier; Hafalla, Julius Clemence R.
title: The importance of the immunodominant CD8+ T cell epitope of Plasmodium berghei circumsporozoite protein in parasite- and vaccine-induced protection
date: 2020-04-05
journal: bioRxiv
DOI: 10.1101/2020.04.03.024539
sha: dc9c5e682172d11c94a6c67e33c3af1a63cecf0e
doc_id: 260927
cord_uid: tjqbrypl

The circumsporozoite protein (CSP) builds up the surface coat of sporozoites and is the leading malaria pre-erythrocytic-stage vaccine candidate. CSP has been shown to induce robust CD8+ T cell responses that are capable of eliminating developing parasites in hepatocytes resulting in protective immunity. In this study, we characterised the importance of the immunodominant CSP-derived epitope, SYIPSAEKI, of Plasmodium berghei in both sporozoite- and vaccine-induced protection in murine infection models. In BALB/c mice, where SYIPSAEKI is efficiently presented in the context of the major histocompatibility complex class I (MHC-I) molecule H-2-Kd, we established that epitope-specific CD8+ T cell responses contribute to parasite killing following sporozoite immunisation. Yet, sterile protection was achieved in the absence of this epitope substantiating the concept that other antigens can be sufficient for parasite-induced protective immunity. Furthermore, we demonstrated that SYIPSAEKI-specific CD8+ T cell responses elicited by viral-vectored CSP-expressing vaccines effectively targeted parasites in hepatocytes. The resulting sterile protection strictly relied on the expression of SYIPSAEKI. In C57BL/6 mice, which are unable to present the immunodominant epitope, CSP-based vaccines did not confer complete protection, despite the induction of high levels of CSP-specific antibodies. These findings underscore the significance of CSP in protection against malaria pre-erythrocytic stages and demonstrate that a significant proportion of the protection against the parasite is mediated by CD8+ T cells specific for the immunodominant CSP-derived epitope.

The circumsporozoite protein (CSP), the major surface coat protein of the malaria sporozoite, 54 has been at the forefront of vaccination studies -being the basis of RTS,S/AS01, the most 55 progressed malaria vaccine candidate to date (9). Immunisation of BALB/c mice 56 with Plasmodium berghei (Pb) or P. yoelii (Py) RAS evokes immunodominant major 57 histocompatibility complex class I (MHC-I) H-2-K d -restricted CD8 + T cell responses against 58 distinct CSP epitopes: SYIPSAEKI for Pb (10) and SYVPSAEQI for Py (11). Indeed, the 59 measurement of responses to these epitopes has become the standard in fundamental 60 immunological studies in BALB/c mice (12) (13) (14) . Furthermore, numerous vaccination studies 61 involving different viral-vectored CSP-or CSP epitope-expressing vaccines -used alone or in 62 combination as part of prime-boost regimens -have corroborated that CSP is a highly 63 protective antigen in the BALB/c infection model (12) (13) (14) (15) (16) (17) (18) . In these studies, elevated levels of 64 either SYIPSAEKI-or SYVPSAEQI-specific CD8+ T cell responses correlated with protection.

Several studies have interrogated and contested the immunological relevance of CSP in 67 parasite-induced protection. These studies emanated from observations that in naturally 68 exposed humans T cell responses to CSP are scarce ( 

In this study, we have extended previous work on the entire CSP by dissecting the relevance 79 of a single CSP-derived immunodominant epitope in parasite-and vaccine-induced protection.

As the most stringent model system, we utilised transgenic Pb parasites lacking SYIPSAEKI 

Sporozoite-induced SYIPSAEKI-specific CD8+ T cell responses contribute to parasite 88 killing but are dispensable for the development of sterile immunity.

First, we interrogated the role that SYIPSAEKI, the H-2-K d -restricted immunodominant epitope 90 of PbCSP, plays in protective immunity induced after live attenuated sporozoite immunisation. 

To ascertain whether SYIPSAEKI contributes to parasite-induced protection, BALB/c mice 105 were immunised once with either PbWT or PbCSP SIINFEKL RAS. Two weeks after immunisation, 106 the mice were challenged with PbWT sporozoites and protection was determined by 107 measuring the parasite loads in the liver 40 hours later (Fig. 1B) . A significant reduction in 108 parasite load -up to four orders of magnitude difference as compared to naïve mice -was 109 observed in mice immunised with PbWT RAS and challenged with PbWT parasites. In contrast, 

To further investigate the requirement of SYIPSAEKI as the indispensable protective epitope 225 of CSP, mice unable to present this epitope were vaccinated with the PbCSP prime-boost 226 regimen with an interval of two weeks between vaccines, followed by challenge with either 227 PbWT or PbCSP SIINFEKL parasites (Fig 3A) . C57BL/6 mice were used because SYIPSAEKI is 228 an H-2-K d restricted epitope, and this mouse strain does not express the relevant MHC-I allele.

Thus, SYIPSAEKI would fail to be presented by infected hepatocytes. As before, blood and 230 serum were derived two weeks after boost. As expected, SYIPSAEKI-specific CD8+ T cells 

RTS,S/AS01, the leading subunit malaria vaccine based on CSP, seems to offer some 303 protection against P. falciparum re-infection (9). Partial and short-lived protection is likely 304 primarily mediated by the action of transitory anti-sporozoite antibodies (30-32). Strikingly,

peripheral blood CD8+ T cell responses were not identified to provide a role following 306 sporozoite challenge in this candidate vaccine. Together with previous findings (7, 14, 16, 21) 307 our data underscore efforts to improve the most advanced candidate malaria vaccine, 308 RTS,S/AS01, by eliciting CD8+ T cells against CSP or other immunodominant antigens. 

Immunofluorescent antibody assay. 10,000 sporozoites were spotted onto epoxy coated 343 glass slides with marked rings (Medco), dried at room temperature and stored at -20°C.

Thawed slides were fixed in acetone, dried and rehydrated with PBS before incubation in 10% 345 FCS supplemented DMEM (Gibco) for 1 hour at 37°C in a humid chamber. Serum at 346 concentrations 1:10 3 , 1:3.3x10 3 , 1:10 4 , 1:3.3x10 4 , 1:10 5 (and, additionally, 1:3.3x10 5 and 1:10 6 347 for C57BL/6 serum) were added to the ring wells and incubated for 1 hour at 37°C in a humid 348 chamber. Slides were washed and stained with a mouse anti-CSP (35) primary antibody.

Hoechst33342 was added as the nuclear stain together with a respective fluorescently labelled 

Peripheral blood was drawn from the tail vein and collected in Na + heparin capillary tubes 357 (Brand) and assayed in 96-well flat bottom plates (Corning). Red blood cells were lysed using 358 PharmLyse (BD) and lymphocytes were resuspended in 10% FCS, 2% Penicillin-Streptomycin 359 and 1% L-glutamine supplemented RPMI 1640 (Gibco). Splenocytes were counted using a 360 40x dilution with Trypan Blue (ThermoFisher Scientific) and a Neubauer 'Improved' 361 haemocytometer (Biochrom). 2x10 6 splenocytes and the lysed blood samples were prepared 362 in 96 well plates and incubated with a final concentration of 10µg/ml of SYIPSAEKI peptide in 363 in the presence of Brefeldin A (eBioScience) for 5-6 hours at 37°C and 5% CO 2 . For staining 364 of cell surface markers and intracellular cytokines, cells were incubated for 1 hour at 4°C for 365 each staining. Cells were stained for CD8 (53-6.7) and CD11a (M17/4) (eBiosience). Splenic 366 cells were fixed with 4% paraformaldehyde and peripheral blood cells were fixed with 1% 20 paraformaldehyde before staining for IFN-g (XMG1.2) (eBioscience) in the presence of 368 Perm/Wash buffer (BD) for intracellular staining. Data was acquired by flow cytometry using 369 an LSRFortessa or LSRII (BD) and analysed using Flowjo9.5.2 (Tree Star, Inc.).

Quantification of parasite load in the liver. Livers were harvested 40-42 hours after 372 sporozoite challenge and total RNA was extracted following homogenisation using TRIzol 373 (ThermoFisher Scientific). cDNA was generated using the RETROScript Kit (Ambion). 

Protective immunity produced by the 412 injection of x-irradiated sporozoites of Plasmodium berghei

Protection of humans against malaria by immunization with radiation

Plasmodium falciparum sporozoites

Protection against malaria by 423 intravenous immunization with a nonreplicating sporozoite vaccine

Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites

The complexity of protective immunity against liver-stage 428 malaria

Memory CD8 T cell responses exceeding a large but definable threshold provide long-term 432 immunity to malaria

Protective CD8+ T lymphocytes in primates immunized with 434 malaria sporozoites

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster 436 dose in infants and children in Africa: final results of a phase 3, individually randomised, 437 controlled trial

Cloned 439 cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against 440 malaria

Cytotoxic T cells recognize a peptide from the circumsporozoite protein on 443 malaria-infected hepatocytes

Priming with recombinant influenza virus followed by administration of recombinant 446 vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria

Single immunizing dose of 449 recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity 450 against malaria

Complete, long-lasting protection against malaria of mice primed and boosted with two 453 distinct viral vectors expressing the same plasmodial antigen

CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a 457 recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes

Induction of protective immunity against 461 malaria by priming-boosting immunization with recombinant cold-adapted influenza and 462 modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the 463 circumsporozoite protein of Plasmodium yoelii

Hill 468 AV. 2010. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara 469 vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell 470 responses

Measuring naturally acquired immune 474 responses to candidate malaria vaccine antigens in Ghanaian adults

Extreme CD8 T cell requirements for 476 anti-malarial liver-stage immunity following immunization with radiation attenuated 477 sporozoites

The circumsporozoite protein is an immunodominant protective antigen in irradiated 480 sporozoites

Sterile protection 483 against malaria is independent of immune responses to the circumsporozoite protein

Dendritic cells 486 and hepatocytes use distinct pathways to process protective antigen from plasmodium in 487 vivo

Tracking the total CD8 T cell response to 489 infection reveals substantial discordance in magnitude and kinetics between inbred and 490 outbred hosts

Evidence of cross-stage CD8+ T cell 492 epitopes in malaria pre-erythrocytic and blood stage infections

Tissue-specific cellular immune responses to malaria pre-494 erythrocytic stages

Identification of targets of CD8(+) T cell responses to malaria liver stages by genome-wide 497 epitope profiling

CD8+ T cells from a novel T cell receptor transgenic mouse induce liver-stage immunity 502 that can be boosted by blood-stage infection in rodent malaria

CD8 T Cell Epitope Derived from Plasmodium berghei Protective Liver-Stage Antigen. Front 505 Immunol

Efficacy of RTS,S/AS01E malaria 510 vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in 511 24 children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

Immunogenicity of the RTS,S/AS01 malaria 518 vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a 519 phase 3 randomised controlled trial

Randomized, 523 double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in 524 malaria-naive adults: safety, efficacy, and immunologic associates of protection

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new 530 vaccine vector

CD8+ T 532 effector memory cells protect against liver-stage malaria

Monovalent fragments (Fab) 534 of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against 535 malarial infection

The Puf-family RNA-binding protein Puf2 controls 537 sporozoite conversion to liver stages in the malaria parasite